Key result
Eight adolescents presented with perimyocarditis within 4 days of receiving a dose of the Pfizer-BioNTech COVID-19 vaccine.
Why the study?
Emergency Use Authorization of the Pfizer-BioNTech COVID-19 vaccine was expanded to include adolescents, prompting the description of subsequent perimyocarditis cases.
Population
8 adolescents with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine
Design
Case series
Authors
Loading...
The BNT162b2 COVID-19 vaccine may be associated with the development of perimyocarditis in adolescents within days of administration.
Case Report (n=8)
No
The BNT162b2 COVID-19 vaccine may be associated with the development of perimyocarditis in adolescents within days of administration.
Tano et al. (2021) conducted a case report in Perimyocarditis (n=8). Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was evaluated on Clinical characteristics of perimyocarditis. Eight adolescents presented with perimyocarditis within 4 days of receiving a dose of the Pfizer-BioNTech COVID-19 vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: